antipyrine has been researched along with erythromycin in 21 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 4 (19.05) | 18.7374 |
1990's | 5 (23.81) | 18.2507 |
2000's | 7 (33.33) | 29.6817 |
2010's | 5 (23.81) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Jolivette, LJ; Ward, KW | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Du-Cuny, L; Mash, EA; Meuillet, EJ; Moses, S; Powis, G; Song, Z; Zhang, S | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Boray, JC; Burrows, GE; Egerton, J; Tasler, J | 1 |
André, P; Descotes, J; Evreux, JC | 1 |
Trzaski, M | 1 |
Babany, G; Breil, P; Funck-Brentano, C; Larrey, D; Pessayre, D; Theodore, C; Vitaux, J | 1 |
Bohlen, DM; Burrows, GE; Burrows, SL; Clarke, CR | 1 |
Erspamer, GF; Erspamer, V; Roseghini, M; Severini, C | 1 |
Tanaka, E; Yasuhara, H | 1 |
Breimer, DD; Tanaka, E | 1 |
CHIBU, K; ICHIMARU, M | 1 |
Schreiber, F; Szewzyk, U | 1 |
Booth, R; Clarke, SJ; Cullinane, C; Francis, P; Hatzimihalis, A; Michael, M; Milner, A; O'Kane, C; Schlicht, S | 1 |
3 review(s) available for antipyrine and erythromycin
Article | Year |
---|---|
Pharmacokinetic drug interactions with macrolide antibiotics.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Antipyrine; Carbamazepine; Drug Interactions; Ergot Alkaloids; Erythromycin; Humans; Kinetics; Pharmaceutical Preparations; Theophylline; Troleandomycin | 1985 |
[Evaluation of liver function in liver diseases using drugs as indicators].
Topics: Aminopyrine; Antipyrine; Erythromycin; Humans; Lidocaine; Liver; Liver Diseases; Liver Function Tests; Trimethadione | 1997 |
In vivo function tests of hepatic drug-oxidizing capacity in patients with liver disease.
Topics: Aminopyrine; Antipyrine; Breath Tests; Caffeine; Chlorzoxazone; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2E1; Cytochrome P-450 Enzyme System; Erythromycin; Humans; Liver Diseases; Liver Function Tests; Trimethadione | 1997 |
3 trial(s) available for antipyrine and erythromycin
Article | Year |
---|---|
Lack of effect of ivermectin on antipyrine and erythromycin disposition in calves.
Topics: Animals; Anthelmintics; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Biotransformation; Cattle; Cross-Over Studies; Drug Interactions; Erythromycin; Female; Injections, Intramuscular; Ivermectin; Liver; Male | 1995 |
Choline esters and biogenic amines in the hypobranchial gland of 55 molluscan species of the neogastropod Muricoidea superfamily.
Topics: Animals; Anthelmintics; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Biotransformation; Cattle; Cross-Over Studies; Drug Interactions; Erythromycin; Injections, Intramuscular; Ivermectin | 1996 |
Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C(14)-erythromycin breath test and the antipyrine clearance test.
Topics: Adult; Aged; Antineoplastic Agents; Antipyrine; Area Under Curve; Breath Tests; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Docetaxel; Dose-Response Relationship, Drug; Erythromycin; Female; Humans; Male; Middle Aged; Phenotype; Taxoids | 2012 |
15 other study(ies) available for antipyrine and erythromycin
Article | Year |
---|---|
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Topics: Algorithms; Animals; Dogs; Haplorhini; Humans; Pharmaceutical Preparations; Pharmacokinetics; Rats; Species Specificity; Tissue Distribution | 2005 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
Topics: Antineoplastic Agents; Blood Proteins; Caco-2 Cells; Cell Membrane Permeability; Computer Simulation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Phosphoproteins; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Quantitative Structure-Activity Relationship | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Antipyrine, erythromycin and oxytetracycline disposition in experimental fasciolosis.
Topics: Animals; Antipyrine; Cattle; Cattle Diseases; Erythromycin; Fascioliasis; Female; Male; Oxytetracycline; Sheep; Sheep Diseases | 1992 |
[Effect of various drugs in vivo and in vitro on the results of the most frequently performed enzymatic determinations in a clinical laboratory].
Topics: Alanine Transaminase; Alkaline Phosphatase; Aminopyrine; Amylases; Antipyrine; Ascorbic Acid; Aspartate Aminotransferases; Chlorpropamide; Clinical Enzyme Tests; Diazepam; Drug Combinations; Enzyme Activation; Enzyme Inhibitors; Erythromycin; Female; Humans; In Vitro Techniques; L-Lactate Dehydrogenase; Male; Pemoline; Phenylbutazone; Poland; Salicylates | 1980 |
Effects of erythromycin on hepatic drug-metabolizing enzymes in humans.
Topics: Adult; Aged; Antipyrine; Cytochrome P-450 Enzyme System; Erythromycin; Female; Humans; Male; Metabolic Clearance Rate; Microsomes, Liver; Middle Aged | 1983 |
[CASE OF AGRANULOCYTOSIS SHOWING A LEUKEMOID REACTION DURING THE RECOVERY PHASE].
Topics: Adrenal Cortex Hormones; Agranulocytosis; Antipyrine; Blood; Bone Marrow Examination; Chloramphenicol; Drug Hypersensitivity; Erythromycin; Laryngitis; Leukemoid Reaction; Pathology; Physiology; Toxicology | 1964 |
Environmentally relevant concentrations of pharmaceuticals influence the initial adhesion of bacteria.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Bacillus subtilis; Bacterial Adhesion; Betaproteobacteria; Erythromycin; Escherichia coli; Ferric Compounds; Polystyrenes; Water Pollutants, Chemical; Water Supply | 2008 |